Association between HTR2C and HTR2A polymorphisms and metabolic abnormalities in patients treated with olanzapine or clozapine.


:Serotonin 2C and 2A receptor (5-HT2C and 5-HT2A) antagonisms are hypothesized to play a role in the metabolic adverse effects induced by olanzapine and clozapine. Associations between polymorphisms in 5-HT2C and 5-HT2A receptor coding genes, HTR2C and HTR2A, with antipsychotic-induced weight gain have been reported. The impact of HTR2C and HTR2A polymorphisms on body mass index (BMI), glucose-insulin homeostasis, and blood lipid levels was evaluated in 46 patients with schizophrenia or schizoaffective disorder and treated with olanzapine (n = 28) or clozapine (n = 18) for at least 6 months. Olanzapine-treated patients with HTR2C haplotype C (-759C, -697C, and 23Ser) had higher BMI (P = 0.029) and C peptide levels (P = 0.029) compared with patients with haplotype B (-759T, -697C, and 23Cys). The frequency of patients homozygous for the HTR2C haplotype A (-759C, -697G, and 23Cys) was significantly higher among clozapine-treated patients with obesity (BMI >/= 30 kg/m) compared with nonobese patients (P = 0.015; odds ratio, 28; 95% confidence interval, 2-380). Patients carrying the HTR2A haplotype 2 (-1438A, 102T, and 452His) had significantly higher C peptide levels compared with haplotype 3 (-1438A, 102T, and 452Tyr) carriers in the olanzapine group (P = 0.034) and in the overall study population (P = 0.019). None of the haplotypes were associated with serum levels of insulin, triglycerides, and cholesterol or with homeostasis model assessment index for insulin resistance. In conclusion, both HTR2C and HTR2A gene polymorphisms seem to be associated with the occurrence of metabolic abnormalities in patients treated with olanzapine or clozapine.


J Clin Psychopharmacol


Gunes A,Melkersson KI,Scordo MG,Dahl ML




Has Abstract


2009-02-01 00:00:00














  • Efficacy of antidepressant medications in children and adolescents with obsessive-compulsive disorder: a systematic appraisal.

    abstract::The aim of this article was to analyze systematically literature information published in English (between 1966 and January 2011) on the efficacy of antidepressants in pediatric obsessive-compulsive disorder. Data were identified through different databases by using variously combined patterns of search terms. Searche...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章,评审


    authors: Gentile S

    更新日期:2011-10-01 00:00:00

  • Alprazolam, propranolol, and placebo in the treatment of panic disorder and agoraphobia with panic attacks.

    abstract::Fifty-five patients completed a 5-week double-blind study comparing alprazolam, propranolol, and placebo in the treatment of panic disorder and agoraphobia with panic attacks. There was no concomitant behavioral treatment. Patient and therapist rating scales included Sheehan's Panic and Anxiety Attack Scales, the Mark...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验


    authors: Munjack DJ,Crocker B,Cabe D,Brown R,Usigli R,Zulueta A,McManus M,McDowell D,Palmer R,Leonard M

    更新日期:1989-02-01 00:00:00

  • Effects of low to moderate acute doses of pramipexole on impulsivity and cognition in healthy volunteers.

    abstract::The neurotransmitter dopamine is integrally involved in the rewarding effects of drugs, and it has also been thought to mediate impulsive behaviors in animal models. Most of the studies of drug effects on impulsive behaviors in humans have involved drugs with complex actions on different transmitter systems and differ...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章


    authors: Hamidovic A,Kang UJ,de Wit H

    更新日期:2008-02-01 00:00:00

  • Self-reported cravings for heroin and cocaine during maintenance treatment with slow-release oral morphine compared with methadone: a randomized, crossover clinical trial.

    abstract:OBJECTIVE:Craving, an urge or increased desire to take a drug, is part of a cluster of behavioral, cognitive, and physiological phenomena that can develop after substance use. Self-reported cravings for heroin and cocaine are compared in opioid dependent patients while receiving maintenance treatment with slow-release ...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章,随机对照试验


    authors: Falcato L,Beck T,Reimer J,Verthein U

    更新日期:2015-04-01 00:00:00

  • Risperidone But Not Quetiapine Treatment Is Associated With Increased Appetite But Not Satiety Hormones in Children During An Oral Glucose Tolerance Test: A Pilot Study.

    abstract:BACKGROUND:Second-generation antipsychotics (SGAs) are commonly used to treat children with mental health conditions (MHCs) but are associated with adverse effects including obesity, hypertension, dyslipidemia, and type 2 diabetes. The mechanisms underlying these complications are unknown, but it has been suggested tha...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章


    authors: Ngai YF,Devlin AM,Panagiotopoulos C

    更新日期:2018-12-01 00:00:00

  • Comparison of the effects of zaleplon, zolpidem, and triazolam on memory, learning, and psychomotor performance.

    abstract::Twenty-four healthy male and female subjects, who participated in this randomized, double-blind, crossover study, received single nighttime doses of zaleplon 10 mg (therapeutic dose), zaleplon 20 mg, zolpidem 10 mg (therapeutic dose), zolpidem 20 mg, triazolam 0.25 mg (positive control), and placebo. Subjective behavi...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验


    authors: Troy SM,Lucki I,Unruh MA,Cevallos WH,Leister CA,Martin PT,Furlan PM,Mangano R

    更新日期:2000-06-01 00:00:00

  • Cognitive effects of a single dose of atypical antipsychotics in healthy volunteers compared with placebo or haloperidol.

    abstract::Cognitive dysfunction in patients with schizophrenia is a strong correlate of poor outcome than any other symptom domain. To have greater knowledge about the effects of antipsychotics on cognitive function, subjects of this study were healthy volunteers who had no confounding variables typically found in patients with...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章,随机对照试验


    authors: Chung YC,Park TW,Yang JC,Huang GB,Zhao T,Oh KY,Kim MG

    更新日期:2012-12-01 00:00:00

  • Predictors for starting depot administration of risperidone in chronic users of antipsychotics.

    abstract:BACKGROUND:Risperidone long-acting injectable (RLAI), the first second-generation depot antipsychotic, has extensively been studied before introduction. Thereafter, questions about the type of patients actually treated with RLAI in daily practice remain to be answered for making valid antipsychotic treatment comparison...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章


    authors: Vehof J,Postma MJ,Bruggeman R,De Jong-Van Den Berg LT,Van Den Berg PB,Stolk RP,Burger H

    更新日期:2008-12-01 00:00:00

  • Donepezil treatment stabilizes functional connectivity during resting state and brain activity during memory encoding in Alzheimer's disease.

    abstract::Previous studies with functional magnetic resonance imaging (fMRI) demonstrated a differential brain activity and connectivity after treatment with donepezil in Alzheimer's disease (AD) when compared to healthy elders. Importantly however, there are no available studies where the placebo or control group included comp...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章,随机对照试验


    authors: Solé-Padullés C,Bartrés-Faz D,Lladó A,Bosch B,Peña-Gómez C,Castellví M,Rami L,Bargalló N,Sánchez-Valle R,Molinuevo JL

    更新日期:2013-04-01 00:00:00

  • Escitalopram administered in the luteal phase exerts a marked and dose-dependent effect in premenstrual dysphoric disorder.

    abstract::This is the first placebo-controlled trial evaluating the efficacy of the selective serotonin reuptake inhibitor (SSRI), escitalopram, in the treatment of premenstrual dysphoric disorder (PMDD). Women with PMDD (intention-to-treat population, n = 151) were treated intermittently for 3 months, during luteal phases only...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章,随机对照试验


    authors: Eriksson E,Ekman A,Sinclair S,Sörvik K,Ysander C,Mattson UB,Nissbrandt H

    更新日期:2008-04-01 00:00:00

  • Quetiapine Extended Release Open-Label Treatment Associated Changes in Amygdala Activation and Connectivity in Anxious Depression: An fMRI Study.

    abstract:BACKGROUND:This study investigated extended release quetiapine (quetiapine XR) associated changes in functional MRI (fMRI) measures of task-induced amygdalar activation and resting state connectivity in anxious unipolar major depressive disorder (AMDD). METHODS:Anxious unipolar major depressive disorder patients (n = ...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章


    authors: Altinay M,Karne H,Beall E,Anand A

    更新日期:2016-12-01 00:00:00

  • Cholinergic challenges in affective illness: behavioral and neuroendocrine correlates.

    abstract::The cholinergic-adrenergic balance hypothesis of affective disorders suggests that, in the areas of the brain that regulate mood, depression may represent a relative predominance of central cholinergic tone over adrenergic tone and that mania may represent the converse. Currently, converging lines of investigation fro...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章


    authors: Risch SC,Kalin NH,Janowsky DS

    更新日期:1981-07-01 00:00:00

  • Therapeutic effect of pirenzepine for clozapine-induced hypersalivation: a randomized, double-blind, placebo-controlled, cross-over study.

    abstract::The objective of this study was to investigate the efficacy of pirenzepine in the treatment of clozapine-induced hypersalivation. Pirenzepine is reported to counteract hypersalivation by its selective antagonistic activity on the M4-muscarinic receptor, which is stimulated by clozapine. Twenty patients with clozapine-...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验


    authors: Bai YM,Lin CC,Chen JY,Liu WC

    更新日期:2001-12-01 00:00:00

  • Platelet monoamine oxidase response to lithium treatment in psychiatric patients.

    abstract::Platelet monoamine oxidase (MAO) activity was studied in bipolar and schizophrenic patients treated with lithium and was found to be increased as a nonspecific drug effect. Greater MAO increase in manic patients was correlated with lesser clinical improvement. There was no correlation of MAO activity with short-term o...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章


    authors: Huang LG,Bowden CL

    更新日期:1984-12-01 00:00:00

  • Persistence of fluphenazine in plasma after decanoate withdrawal.

    abstract::We discontinued fluphenazine decanoate using a double-blind, crossover random order design, in 12 recent onset clinically stable schizophrenics who had been given fluphenazine decanoate 12.5 mg intramuscularly every 2 weeks for at least 1 year prior to drug withdrawal. Each condition (drug or placebo) lasted 12 weeks....

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验


    authors: Gitlin MJ,Midha KK,Fogelson D,Nuechterlein K

    更新日期:1988-02-01 00:00:00

  • Paliperidone Palmitate Once-Monthly Injectable Treatment for Acute Exacerbations of Schizoaffective Disorder.

    abstract::The optimal treatment for schizoaffective disorder (SCA) is not well established. In this initial 6-month open-label treatment period of a large, multiphase, relapse-prevention study, the efficacy and safety of paliperidone palmitate once-monthly (PP1M) injectable were evaluated in subjects with symptomatic SCA. Subje...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章


    authors: Fu DJ,Turkoz I,Simonson RB,Walling D,Schooler N,Lindenmayer JP,Canuso C,Alphs L

    更新日期:2016-08-01 00:00:00

  • The Effect of Clozapine on Hematological Indices: A 1-Year Follow-Up Study.

    abstract::Clozapine is the antipsychotic of choice for treatment-resistant schizophrenia and is linked to a need for mandatory hematological monitoring. Besides agranulocytosis, other hematological aberrations have resulted in premature termination in some cases. Considering clozapine's role in immunomodulation, we proceeded to...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章


    authors: Lee J,Takeuchi H,Fervaha G,Powell V,Bhaloo A,Bies R,Remington G

    更新日期:2015-10-01 00:00:00

  • Description of the Treatment Course by Pregabalin for Anxiety in Patients With a Major Neurocognitive Disorder.

    abstract:BACKGROUND:Anxiety symptoms frequently experienced by patients with a major neurocognitive disorder (NCD) are often treated with long-term benzodiazepines despite known adverse effects. Pregabalin has shown efficacy in generalized anxiety disorders but has not been studied in patients with a major NCD. The objective of...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章


    authors: Novais T,Doutone A,Gombault C,Krolak-Salmon P,Lepetit A,Mouchoux C

    更新日期:2019-05-01 00:00:00

  • Aripiprazole in schizophrenia with cocaine dependence: a pilot study.

    abstract::The debilitation of schizophrenia (SCHZ) worsens markedly with comorbid cocaine dependence (CD) and alcohol abuse. To date, no medications have conclusively demonstrated effects against both SCHZ and CD (SCHZ + CD) simultaneously. Because of its dopamine-modulating properties, we hypothesized that aripiprazole would a...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章


    authors: Beresford TP,Clapp L,Martin B,Wiberg JL,Alfers J,Beresford HF

    更新日期:2005-08-01 00:00:00

  • Pharmacokinetic-Pharmacodynamic Characterization of Relapse Risk for Paliperidone Palmitate 1-Month and 3-Month Formulations.

    abstract:BACKGROUND:Pharmacokinetic-pharmacodynamic (PK/PD) models were developed to describe the relationship between the time course of paliperidone plasma concentrations and the risk of relapse of schizophrenia symptoms following administration of paliperidone palmitate 1-month (PP1M) and 3-month (PP3M) long-acting injectabl...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章,多中心研究,随机对照试验


    authors: Russu A,Savitz A,Mathews M,Gopal S,Feng Y,Samtani MN

    更新日期:2019-11-01 00:00:00

  • Idazoxan, an alpha 2 antagonist, augments fluphenazine in schizophrenic patients: a pilot study.

    abstract::Idazoxan, a selective alpha 2-adrenergic antagonist, was added to stable doses of fluphenazine treatment in six patients with schizophrenia who participated in a double-blind, placebo-controlled pharmacologic study. Compared with fluphenazine alone, combining idazoxan (mean dose, 120 mg/day) with fluphenazine (mean do...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验


    authors: Litman RE,Hong WW,Weissman EM,Su TP,Potter WZ,Pickar D

    更新日期:1993-08-01 00:00:00

  • Monoamine oxidase inhibitor therapy for anorexia nervosa and bulimia: a preliminary trial of isocarboxazid.

    abstract::In an open prospective clinical study, 14 female outpatients with anorexia nervosa or bulimia completed a 6-week trial of isocarboxazid, with a mean dose of 34 mg. The eight bulimic and six restrictive anorexic subjects did not show any significant differences in medication response. Ratings of depression and anxiety ...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章


    authors: Kennedy SH,Piran N,Garfinkel PE

    更新日期:1985-10-01 00:00:00

  • The clinical use of anticholinergic drugs as treatment for extrapyramidal side effects of neuroleptic drugs.

    abstract::The clinician using neuroleptic drugs for the treatment of psychotic patients must face a number of questions regarding whether and how to use anticholinergic drugs when extrapyramidal side effects appear. This article explores some of these questions, suggests how they might best be answered, reviews the studies whic...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章


    authors: McEvoy JP

    更新日期:1983-10-01 00:00:00

  • Does nefazodone improve both depression and Parkinson disease? A pilot randomized trial.

    abstract::Some of the selective serotonin reuptake inhibitors (SSRI)-induced motor side effects are mediated by stimulating 5-HT2 receptors in the basal ganglia, probably because serotonin inhibits the subsequent neuronal dopamine release. We hypothesized that nefazodone, a serotonin 2 antagonist/reuptake inhibitor (SARI) that ...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验


    authors: Avila A,Cardona X,Martin-Baranera M,Maho P,Sastre F,Bello J

    更新日期:2003-10-01 00:00:00

  • Olanzapine plasma concentrations and clinical response in acutely ill schizophrenic patients.

    abstract::Olanzapine is an atypical antipsychotic effective in the treatment of schizophrenic patients. After a 2- to 9-day placebo lead-in, 79 inpatients with schizophrenia according to DSM-III-R criteria were placed on an olanzapine dosage of 10 mg/day or 1 mg/day for up to 6 weeks. Blood samples were obtained weekly during t...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章,多中心研究


    authors: Perry PJ,Sanger T,Beasley C

    更新日期:1997-12-01 00:00:00

  • Pharmacokinetics of benzodiazepines and psychostimulants in children.

    abstract::The pharmacokinetics of benzodiazepines and psychostimulants are reviewed and an overview of the kinetic principles relevant to the utilization of these drugs in infancy and childhood is provided. Newborns and premature infants can metabolize and eliminate diazepam, although the parent drug has a longer half-life and ...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章


    authors: Coffey B,Shader RI,Greenblatt DJ

    更新日期:1983-08-01 00:00:00

  • Clonidine improves hyperarousal in borderline personality disorder with or without comorbid posttraumatic stress disorder: a randomized, double-blind, placebo-controlled trial.

    abstract::The Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition borderline personality disorder (BPD) seems to constitute a very heterogeneous category. Therefore, pharmacological therapy is symptom-oriented or targets comorbid conditions. A high comorbidity exists between BPD and posttraumatic stress disord...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章,随机对照试验


    authors: Ziegenhorn AA,Roepke S,Schommer NC,Merkl A,Danker-Hopfe H,Perschel FH,Heuser I,Anghelescu IG,Lammers CH

    更新日期:2009-04-01 00:00:00

  • Effect of erythromycin on tricyclic antidepressant metabolism.

    abstract::Macrolide antibiotics such as erythromycin have been found to impair the hepatic metabolism of carbamazepine. In addition, recent studies have shown that intestinal flora can N-demethylate tricyclic antidepressants, suggesting that the human gut may be a possible site of extrahepatic drug metabolism. Therefore, we con...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章


    authors: Amsterdam JD,Maislin G

    更新日期:1991-06-01 00:00:00

  • Paliperidone extended-release in schizoaffective disorder: a randomized, controlled study comparing a flexible dose with placebo in patients treated with and without antidepressants and/or mood stabilizers.

    abstract::This 6-week, double-blind, placebo-controlled study evaluated paliperidone extended-release (ER) as both monotherapy and adjunctive therapy to mood stabilizers and/or antidepressants (MS/ADs) for schizoaffective disorder. Included subjects had a schizoaffective disorder diagnosis; a Positive and Negative Syndrome Scal...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 杂志文章,多中心研究,随机对照试验


    authors: Canuso CM,Schooler N,Carothers J,Turkoz I,Kosik-Gonzalez C,Bossie CA,Walling D,Lindenmayer JP

    更新日期:2010-10-01 00:00:00

  • The side effects burden of extended imipramine treatment of panic disorder.

    abstract::In a recent study, the authors gauged the net effectiveness of imipramine to be 53%; that is, of 110 patients having panic disorder with agoraphobia who started a course of imipramine at a fixed, targeted, weight-adjusted dose of 2.25 mg x kg(-1) x day(-1), 59 adhered to the regimen and showed a marked and stable resp...

    journal_title:Journal of clinical psychopharmacology

    pub_type: 临床试验,杂志文章,随机对照试验


    authors: Mavissakalian MR,Perel JM

    更新日期:2000-10-01 00:00:00